INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 195 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2015. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $9,230,000 | -17.5% | 116,000 | +16.0% | 1.26% | +23.7% |
| Q1 2019 | $11,186,000 | +208.0% | 100,000 | +233.3% | 1.02% | +65.5% |
| Q2 2017 | $3,632,000 | +114.0% | 30,000 | +100.0% | 0.62% | +85.8% |
| Q1 2017 | $1,697,000 | -41.5% | 15,000 | -14.3% | 0.33% | -10.3% |
| Q3 2015 | $2,903,000 | -31.3% | 17,500 | 0.0% | 0.37% | -10.6% |
| Q2 2015 | $4,224,000 | -0.1% | 17,500 | +16.7% | 0.41% | -5.9% |
| Q1 2015 | $4,230,000 | +171.2% | 15,000 | +50.0% | 0.44% | +65.4% |
| Q4 2014 | $1,560,000 | -54.7% | 10,000 | -31.3% | 0.27% | -37.6% |
| Q3 2014 | $3,447,000 | – | 14,565 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |